Ivonescimab Injection + Pembrolizumab Injection
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Feb 27, 2025 → Jun 1, 2029
NCT ID
NCT06767514About Ivonescimab Injection + Pembrolizumab Injection
Ivonescimab Injection + Pembrolizumab Injection is a phase 3 stage product being developed by Summit Therapeutics for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06767514. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06767514 | Phase 3 | Recruiting |
| NCT05899608 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer